LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PF431396 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2483 | 5752 | 0.4318 | -0.0200 |
| SK-BR-3 | PF431396 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 2286 | 5752 | 0.3975 | -0.0866 |
| SK-BR-3 | PF431396 | 10 | uM | LJP5 | 72 | hr | 2543 | 1530 | 5752 | 0.2661 | -0.3506 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5304 | 5418 | 0.9802 | 0.9665 |
| SK-BR-3 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5058 | 5418 | 0.9346 | 0.8816 |
| SK-BR-3 | Celastrol | 0.37 | uM | LJP6 | 72 | hr | 2543 | 2278 | 5418 | 0.4209 | -0.0958 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1758 | 5418 | 0.3248 | -0.2872 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1514 | 5418 | 0.2797 | -0.3785 |
| SK-BR-3 | Celastrol | 10 | uM | LJP6 | 72 | hr | 2543 | 1765 | 5418 | 0.3261 | -0.2845 |
| SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6256 | 5752 | 1.0876 | 1.1478 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5996 | 5752 | 1.0424 | 1.0717 |
| SK-BR-3 | SU11274 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 6036 | 5752 | 1.0494 | 1.0834 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5770 | 5752 | 1.0030 | 1.0049 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5612 | 5752 | 0.9757 | 0.9587 |
| SK-BR-3 | SU11274 | 10 | uM | LJP5 | 72 | hr | 2543 | 2510 | 5752 | 0.4365 | -0.0110 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2669 | 5418 | 0.4928 | 0.0449 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 2262 | 5418 | 0.4179 | -0.1016 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1983 | 5418 | 0.3664 | -0.2038 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1841 | 5418 | 0.3398 | -0.2569 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1788 | 5418 | 0.3304 | -0.2759 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 72 | hr | 2543 | 1508 | 5418 | 0.2785 | -0.3809 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5921 | 5752 | 1.0294 | 1.0499 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5618 | 5752 | 0.9768 | 0.9604 |
| SK-BR-3 | NVP-AEW541 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5650 | 5752 | 0.9823 | 0.9699 |
| SK-BR-3 | NVP-AEW541 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5537 | 5752 | 0.9627 | 0.9362 |